Programs in Metabolism and Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Diabetes Care. 2024 Oct 1;47(10):1731-1739. doi: 10.2337/dc23-1691.
Individuals with diabetes who carry genetic variants that lower hemoglobin A1c (HbA1c) independently of glycemia may have higher real, but undetected, hyperglycemia compared with those without these variants despite achieving similar HbA1c targets, potentially placing them at greater risk for diabetes-related complications. We sought to determine whether these genetic variants, aggregated in a polygenic score, and the large-effect African ancestry-specific missense variant in G6PD (rs1050828) that lower HbA1c were associated with higher retinopathy risk.
Using data from 29,828 type 2 diabetes cases of genetically inferred African American/African British and European ancestries, we calculated ancestry-specific nonglycemic HbA1c polygenic scores (ngA1cPS) composed of 122 variants associated with HbA1c at genome-wide significance, but not with glucose. We tested the association of the ngA1cPS and the G6PD variant with retinopathy, adjusting for measured HbA1c and retinopathy risk factors.
Participants in the bottom quintile of the ngA1cPS showed between 20% and 50% higher retinopathy prevalence, compared with those above this quintile, despite similar levels of measured HbA1c. The adjusted meta-analytic odds ratio for the bottom quintile was 1.31 (95% CI 1.0, 1.73; P = 0.05) in African ancestry and 1.31 (95% CI 1.15, 1.50; P = 6.5 × 10-5) in European ancestry. Among individuals of African ancestry with HbA1c below 7%, retinopathy prevalence was higher in individuals below, compared with above, the 50th percentile of the ngA1cPS regardless of sex or G6PD carrier status.
Genetic effects need to be considered to personalize HbA1c targets and improve outcomes of people with diabetes from diverse ancestries.
与不携带这些变体的个体相比,独立于血糖降低血红蛋白 A1c(HbA1c)的糖尿病个体可能具有更高的真实但未被检测到的高血糖,尽管他们达到了相似的 HbA1c 目标,这可能使他们面临更大的糖尿病相关并发症风险。我们试图确定这些遗传变异,聚合在一个多基因评分中,以及降低 HbA1c 的大型非洲裔特有的错义变体 G6PD(rs1050828)是否与更高的视网膜病变风险相关。
使用来自 29828 例遗传推断的非裔美国/非裔英国和欧洲血统 2 型糖尿病病例的数据,我们计算了由 122 个与 HbA1c 相关的、在全基因组水平上具有显著性但与葡萄糖无关的非血糖 HbA1c 多基因评分(ngA1cPS)组成的非洲裔特异性非血糖 HbA1c 多基因评分(ngA1cPS)。我们测试了 ngA1cPS 和 G6PD 变体与视网膜病变的相关性,同时调整了测量的 HbA1c 和视网膜病变危险因素。
尽管测量的 HbA1c 水平相似,但 ngA1cPS 处于最低五分位的参与者的视网膜病变患病率比高于该五分位的参与者高 20%至 50%。非洲裔血统的调整后的荟萃分析比值比为 1.31(95%CI 1.0,1.73;P = 0.05),欧洲血统的为 1.31(95%CI 1.15,1.50;P = 6.5×10-5)。在 HbA1c 低于 7%的非裔个体中,无论性别或 G6PD 携带者状态如何,ngA1cPS 第 50 百分位以下的个体的视网膜病变患病率均高于该百分位以上的个体。
需要考虑遗传效应来个性化 HbA1c 目标,并改善来自不同血统的糖尿病患者的结局。